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Abstract 
RNA interference (RNAi) involves the specific repression of the translation of a 
gene through mRNA degradation. Its application has been extended to a variety 
of studies both in vitro and in vivo. The Ber-Ab/ translocation is the cytogenetic 
marker for chronic myelogenous leukemia (CML) and has been studied 
extensively. The K-562 cell line possesses the Ber-Ab/ fusion gene and has been 
established as a model for RNAi. lmatinib mesylate (Gleevec) is a proven 
specific inhibitor of the Bcr-Abl tyrosine kinase. The aim of this study was to 
combine K-562 cells primed with short inte,rfering RNA (siRNA) targeting the Ber­
Abl fusion site with treatment with Gleevec. Two different preparations of siRNA: 
homogenous-synthetic Ber-Ab/ and heterogeneous-transcribed-digested Ber-Ab/ 
were used to silence the Ber-Ab/ fusion gene. The synthetic siRNA consisted of a 
homogenous mixture of 21nt long double stranded RNA duplexes specific for the 
Ber-Ab/ fusion site. The transcribed-digested Ber-Ab/ siRNA were generated 
using an in vitro transcription method producing a 450 bp cloned fragment with 
the Ber-Ab/ fusion site in the center of the cloned region. This cloned fragment 
was further digested with RNAse 'Ill to produce a heterogeneous mixture of Ber­
Abl 19-21 nt siRNA duplexes. We demonstrated a 70% down-regulation of the 
Ber-Ab/ mRNA through real time PCR and RT-PCR as well as a 75% down­
regulation of the Bcr-Abl and Bcl-xL proteins in K-562 cells transfected with 
synthetic Ber-Ab/ siRNA. The ICso of Gleevec alone in the K-562 subline F 1 was 
lowered from 0.2µM to 0.06µM in cells transfected with both preparations of Ber­
Abl siRNA, while no effect was observed in an irrelevant siRNA control. This 
Vl1 
suggests an additive relationship between Gleevec and Bcr-Ab/-specific-siRNA 
treated cells. An increase in apoptosis was also seen in K-562 cells primed with 
Ber-Ab/ siRNA and treated with Gleevec indicating the additive relationship 
between Gleevec and Ber-Ab/ siRNA. These results indicate that priming K-562 
cells with Ber-Ab/ siRNA correlate with a decrease in the effective dose of 
Gleevec required to inhibit the Bcr-Abl protein. 
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Chapter 1 
Review of the Literature 
Introduction 
RNA interference (RNAi) is a pathway that targets specific transcripts and 
results in gene-specific silencing (1-9). The ability to .target and interfere with 
specific RNA has been used in a variety of studies ranging from gene modulation 
to screening for specific gene function and disease intervention (10-13). The 
potency and efficacy of RNAi surpasses other known methods of transcriptional 
down-regulation such as antisense and has a longer sustained effect of 
transcriptional repression (14-16). Recently, focus has been placed on the 
delivery of RNAi, for which there have been significant advances making the 
application of RNAi attainable for both in vitro and in vivo applications (17, 18). 
RNAi promises to revolutionize genetics by providing the ability to knock down 
the expression of any gene (19, 20). 
In chronic myelogenous leukemia, (CML) the molecular marker of 
malignancy is the presence of the breakpoint-cluster-region/Ableson (Ber-Ab/) 
oncogene (21-23). This marker is not present in normal cells and the Abl 
transcript and polypeptide are highly restricted in their expression (24). 
Therefore, the Ber-Ab/ fusion gene is an ideal target for RNAi analysis and 
therapy (25, 26). The K-562 cell line is a CML derivative that expresses high 
levels of the Ber-Ab/ fusion gene, making it a rigorous model for in vitro studies of 
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RNAi (27). To date, various forms of RNAi have been applied in vitro in studies 
using various cell lines, including K-562 (28-31). 
lmatinib mesylate (Gleevec) is a specific tyrosine kinase inhibitor that 
targets the Bcr-Abl oncoprotein (32-37). It has had success used as a clinical 
therapeutic agent for CML (36). Bcr-Abl confers resistance to apoptosis; thus, 
inhibition of Bcr-Abl with agents such as Gleevec renders cells susceptible to 
apoptosis (37, 38). Gleevec has been shown to inhibit the proliferation of K-562 
cells and, eventually, lead to differentiation, apoptosis and cell death in vitro (34, 
37, 39). Gleevec shows synergism when administered in conjunction with a 
number of different agents, including interferon-a, etoposide, and daunorubicin in 
K-562 cells (40, 41). This observation supports the focus of this study, which is to 
investigate possible synergistic effects of the combination of with Bcr-Abl-RNAi 
with Gleevec using K-562 cells. Thus, targeting the protein substrate-binding S'ite 
of the Bcr-Abl protein in tandem with the Ber-Ab/ transcript provides two separate 
methods of inhibition for the same molecular target. 
Chronic Myelogenous Leukemia 
Chronic myelogenous leukemia (CML) presents with elevated levels of 
myeloid and erythroid cells in peripheral blood and with marked myeloid 
hyperplasia in the bone marrow (21 ). The disease exhibits three phases: the 
chronic phase, lasting 3 to 5 years; the accelerated phase, with marked 
hypermetabolism and intramedullary expansion of leukemic cells; and blast 
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crisis, confirmed by greater than 30% blasts in the peripheral blood and/or bone 
marrow (42). 
CML is a clonal hematopoietic malignancy identified by the Philadelphia 
(Ph) chromosome, which is found in 95% of CML patients (22, 43). The Ph 
chromosome results from the t(9q34;22q11) translocation, where the 5' end of 
the Abelson (c-ab/) gene from chromosome 9 is relocated onto the 3' end of the 
Breakpoint cluster region (c-bc1' gene on chromosome 22 in a head to tail 
manner (43).The Ph chromosome was the earliest specific chromosome 
rearrangement identified in a malignancy and has been cloned and characterized 
at the molecular level (23, 44). The cytogenetic evolution pattern correlates with 
the clinical behavior of a disease (44). 
Bcr-Abl Fusion 
The t(9q34;22q11) translocation results in the chimeric gene, Ber-Ab/, 
which is transcribed into an 8.5 kb hybrid mRNA, and translated into the Bcr-Abl 
fusion protein (Figure 1) (45). The breakpoint in the Ab/ gene can occur 
anywhere within the 300kb 5'end of the gene, upstream of the first alternative 
exon lb, between exons lb and la, or downstream of exon la (46). In contrast, the 
vast majority of CML patients possess a breakpoint in the Ber gene within a 
5.8kb region known as the major breakpoint cluster region (M-bc1', spanning 5 
exons from exons 12 to 16, referred to as b1 to b5 (24, 46-48). 
The Bcr-Abl fusion protein is a constitutively activated cytoplasmic tyrosine 
kinase of 210 kD, 902 amino acids in length, and is complexed in vivo with both 
3 
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Figure 1. The Bcr-Abl fusion protein. The origin of the Bcr-Abl 
fusion protein, the Philadelphia chromosome, results from the 
translocation of c-Bcr from chromosome 22 onto c-Abl located on 
chromosome 9 in a head to tail manner. 
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p160 Ber and ph-P53 proteins (21, 49, 50). Protein tyrosine kinases are 
members of a group of enzymes that bind ATP and catalyze the transfer of the y­
phosphate to the hydroxy group of a tyrosine residue on a protein (32). The 
phosphorylated substrates can then serve as binding sites for other substrates, 
carrying out the signal transduction cascade of a variety of pathways (32). 
Many intracellular pathways are directly affected by the expression of the 
Bcr-Abl protein (Figure 2) (51 ). The substrates targeted by Bcr-Abl include CRKL, 
p62Dok, paxillin, CBL and RIN, which are integral in pathways involving Pl3-
kinase, Akt, ERK JUN kinase, MAP, Myc, STAT, and Ras/Raf (21, 52-54). Bcr­
Abl initiates the Ras/Raf/MEK/ERK, JAK/STAT, Pl3K/Akt signal transduction 
pathways, resulting in cell proliferation (51, 55, 56). 
Ber-Ab/ fusion in hematopoietic cell lines abrogates their dependency on 
growth factors for proliferation and survival (54). The constitutive tyrosine kinase 
activity of the nascent Bcr-Abl oncoprotein provides the transforming ability (57, 
140). The expression of Bcr-Abl in mice induces a disease similar to CML, which 
corroborated the role of Bcr-Abl as a transforming agent of malignancy (50). 
Although the role of the Ber gene is not fully understood, it is expressed 
ubiquitously, with the highest mRNA levels found in the brain and hematopoietic 
cells (24). Ber protein levels are elevated in the early stages of myeloid 
differentiation, and levels dropped significantly as cells mature to 
polymorphonuclear leukocytes (24). The Ber protein has also been linked to 
cytoskeletal reorganization, and DNA repair (24). While the intracellular role of 
5 
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Figure 2. Bcr-Abl pathway interactions. The expression of Bcr-Abl 
modulates the Ras/Raf, P13K, Jak/STAT and MEK/ERK pathways, 
leading to multiple proliferative and antiapoptotic outcomes. Bcr-Abl 
activation follows the binding of the oligomerization domain in the 
Ber protein onto the tyrosine kinase region of the Abl protein. The 
Abl protein then phosphorylates Tyr1 n in the Ber protein leading to 
proliferation. 
. .  , . • 
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Ber has not been determined in normal cells, its suggested function in CML cells 
is as a negative regulator of Bcr-Abl kinase activity (58). The removal of the 
oligomerization domain, the first 63 amino acid residues of the Ber 
serine/threonine kinase, results in a truncated Ber moiety . resistant to 
autophosphorylation by the activated Abl tyrosine kinase and limited transforming 
ability (24, 57, 58). This truncated Ber protein strongly inhibits the Bcr-Abl kinase 
activity (58). Arlinghaus et al. demonstrated Bcr-Abl inactivating normal Ber 
through phosphorylation (58). This observation supports the role of the activated 
Ber kinase as inhibiting the Bcr-Abl kinase and asserts the function of Bcr-Abl as 
deactivating the Ber serine/threonine kinase, propagating the deregulation of the 
Bcr-Abl tyrosine kinase activity (58). The normal function of the Abl protein is 
primarily as a tyrosine kinase, and Abl is differentially phosphorylated during the 
cell cycle (24, 59, 60). Abl associates with cell cycle proteins Rb, p53, p73, Atm, 
and cyclin D and overexpression of Abl leads to growth arrest (24, 45). Since 
normal cells lack the Bcr-Abl fusion protein, it represents a selective site for 
intervention (32). 
K-562 Cell Line 
The K-562 cell line is an undifferentiated leukemic line derived from the 
plural effusion of a CML patient in blast crisis (61, 62). These cells were first 
observed to maintain their Philadelphia chromosome positive, Ph (+), status 
through 175 serial passages over 3 ½ years (61). In 1975, 1-4 Ph chromosomes 
were detected in each cell (61). Several atypical Ph chromosomes, common in 
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K-562 cells, result in an increased amount of Bcr-Abl oncogene expression (27, 
63). When compared to standard patient samples, K-562 cells were reported to 
have a 82-fold overproduction of the Bcr-Abl transcript in 1994 and a 200-fold 
overproduction of the Bcr-Abl transcript in 1997 (27). In the K-562 cell line, the 
fusion site of. the Bcr-Abl gene is between the Ber exons b3 and b4 and between 
the Abl exons a1 and a2, resulting in the b3a2 variant (46). Expression of Bcr­
Abl by the K-562 cell line was found to impart resistance to apoptosis induction in 
response to various cytotoxic drugs or serum deprivation (52). 
Gleevec 
STl-571 (imatinib mesylate, or Gle�vec) (Figure �) is a Ber-Ab/- specific 
tyrosine kinase inhibitor (32, 64 ). Gleevec has been termed the "gold standard" in 
treatment of chronic myelogenous leukemia due to its specificity (36, 65, 66). The 
Bcr-Abl protein is a cytosolic tyrosine kinase that does not depend on ligand 
binding and subsequent receptor dimerization for activation (32). This aspect of 
Ber-Ab/ results in an inability to modulate its activity with receptor-based 
inhibitors (32). The limited sequence variation surrounding the ATP-binding site, 
as well as the conformational differences between inactive and active forms of 
kinases, offer sources for inhibition (67). Gleevec works as an ATP-competitive 
inhibitor of the Ber-Ab/ kinase activity (32). From the crystal structure, it was 
shown that Gleevec binds to c-Abl via a series of H-bond interactions and van 
der Waals contacts with specific amino acid residues (32). Mutations in these 
amino acids result in resistance to Gleevec (32). While Gleevec is a potent 
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STl-571 (a.k.a. imatinib or Gleevec®) 
Figure 3. Structure of Gleevec. imatinib mesylate or Gleevec has a 
relative molecular mass of 589.7 with a molecular formula of C29H31N10 
• CH4SQ3 and a chemical formula 4-[(4-Methyl-1-piperazinyl) methyl]-N­
[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl] amino]-phenyl] benzamide 
methanesulfonate. Figure from Novartis (32). 
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competitive inhibitor of c-Abl, and also interferes with c-Kit and PDGFR-J3, it is 
inactive against any other tyrosine kinases (32). 
In vitro studies of Gleevec, using Bcr-Abl-expressing cell lines including 
K-562, have demonstrated an antiproliferative effect (33, 68, 69). Gleevec kills 
leukemic cells in vitro and in vivo through an apoptosis-mediated mechanism (34, 
68, 70). Apoptosis was detected measuring caspase 3 activity and the release of 
cytochrome c from the mitochondria, which are both hallmarks of apoptosis (34, 
68, 71). The apoptotic mechanism that Gleevec triggers involves the downstream 
inactivation of the Bcl-2 family protein, Bcl-xL (34, 39, 72). This protein is also 
constituitively activated through autophosphorylation by Bcr-Abl (39). Oetzel et 
a/. showed that Gleevec caused the downregulation of Bel-XL, resulting in 
susceptibility to programmed cell death, while there was no change in the level of 
Bcl-2 (34). Gleevec also mediated a decrease in Akt kinase activity and an 
increase in the Apo-2L/TRAIL-induced apoptosis of K-562 cells (73). 
Although Gleevec has specificity and efficacy, the required length of the 
treatment, which may be extended for the length of a person's life, can result in 
the development of resistant clones (73-76). There is evidence of a number of 
mechanisms responsible for the development of Gleevec-resistant CML clones, 
such as increased production of the Bcr-Abl transcript number, increases in the 
expression of the Bcr-Abl protein, point mutations in the ATP binding pocket or 
other functional sites, and increased drug efflux (32, 74, 77-80). 
10 
Gene Silencing 
Gene silencing is defined as the silencing of the translation of a specific 
gene (19, 81). This concept has been applied successfully both in vitro and in 
vivo (1, 2, 10, 18, 19, 82). Antisense technology has been applied over the past 
decade with some-success (14, 83, 84). Antisense interference involves either 
antisense DNA (oligodeoxynucleotides, ODN) or RNA homologous to the specific 
region of the mRNA (14). These ODNs are transfected into cells and 
subsequently hybridize to the specific region within a particular mRNA transcript 
(14). This binding inhibits translation of the message (14). Antisense interference 
is related to RNAi, which also specifically targets mRNA (14, 85). It is noteworthy 
that the stability of single-stranded antisense ODNs is considerably less than that 
of double stranded RNA, which results in less efficient silencing (28). 
New evidence supports multiple functions for gene silencing in a variety of 
biological processes, including antiviral defense, embryonic development, and 
maintenance of genomic stability (86-89). Gene silencing is referred to as RNAi 
in animals, post-transcriptional gene silencing (PTGS) or co-suppression in 
plants and quelling in fungi (86, 90, 91 ). Although the processes share some 
similar steps and result in specific targeting of mRNA, there are distinctive 
differences in the proteins involved, the length of the effect, and the ability to 
exhibit gene repression (6, 10, 19, 92). While the silencing effect is pronounced 
in mammals, normal gene expression generally returns in 9 to 11 days (5). 
The phenomenon of PTGS was first discovered in plants over a decade 
ago and involves specific targeting of a gene and degradation of the mRNA 
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resulting in a block in translation of the protein encoded by the silenced gene (1, 
93). The process of PTGS is believed to have co-evolved with its viral antagonist 
to function as a primitive immune response against the invasion of foreign nucleic 
acids presented through viral infections and transposons and retroposons (3). 
This theory is supported by the observation that certain viruses are able to 
overcome or prevent mRNA degradation by expressing proteins that suppress 
PTGS (5). Most plant viruses possess single-stranded RNA genomes, which are 
replicated by the virus-encoded RNA-dependent RNA polymerase to produce 
both sense and antisense strands of RNA (19). These strands have the potential 
to hybridize to form double-stranded RNA (10). Once dsRNA, a marker for viral 
infection, is detected in the cell, the process of PTGS is initiated (10). 
The first proposed mechanism to explain RNAi was set forth by Bass and 
was based on the introduction of dsRNA directly into cells to be degraded and 
used in gene silencing (94). Bass proposed that the dsRNA introduced into the 
cell is, in turn, targeted by an endonuclease which then cleaves 1it to short, -23nt, 
dsRNA, also referred to as short interfering RNA (siRNA), which bind to and 
promote degradation of the free mRNA (94). This endonuclease, later termed the 
Dicer enzyme, is a member of the Argonaute protein family (95). It is an initiator 
of the formation of a 3-protein complex known as the RNA-induced silencing 
complex (RISC) with the siRNA for mRNA degradation (95). 
The first animal application for this technique came in Caenorhabditis 
elegans where it was discovered that, as in the plant system, gene down­
regulation could be heritable due to the presence of the enzyme, RNA-dependent 
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RNA polymerase (RdRp) (2, 96). The plant and C. elegans mechanism are 
similar in that dsRNA has catalytic si lencing capabil ities, while single stranded 
RNA gets degraded upon delivery into the cell (2) . The mechanism by which 
plants and nematodes undergo gene si lencing has been referred to as the 
"guide- primer" model , (Figure 4) where the Dicer enzyme cleaves double­
stranded RNA to make short interfering (siRNA) (92). The Dicer enzyme unwinds 
the siRNA, and the antisense strand of the siRNA duplex binds to the 
homologous region of mRNA (92). These siRNAs serve as a guide-primer with 
RdRp to convert the mRNA into double stranded RNA to be digested by the 
Dicer enzyme (92) . This process is propagated indefinitely due to the recycl ing of 
the template siRNA and the stabil ity of both the RdRp and Dicer enzymes (92). 
The assertion that siRNAs are catalytic in nature is supported by the requi rement 
of only a few siRNA molecules to mount a sufficient RNAi response (6, 97) . 
The mammal ian model for gene si lencing has been termed the 
"endonucleocytic-cleavage" model (Figure 5) , which involves a group of proteins 
known as the RNA-induced silencing complex (RISC) (2, 92, 93, 98) . The 
proteins included in the mammalian RISC are EIF2C2, Gemin3 and Gemin4, and 
an endonuclease, Slicer, activated by a hel icase domain located on the Dicer 
enzyme (95, 98) . This activation results in the unwinding of the double-stranded 
siRNA, leaving the antisense strand of RNA bound to the activated RISC 
complex (92). This siRNA serves as a template for sequence-specific targeted 
degradation of mRNA (92, 94) . The "endonucleocytic cleavage" model proposes 
that the activated RISC complex binds the single-stranded mRNA template to be 
1 3  
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Figure 4. The "guide-primer'' model. The guide-primer mechanism for 
gene silencing begins with the cleavage of double-stranded RNA into 
siRNA by the Dicer enzyme, Panel A, followed by the unwinding of the 
siRNA duplex by a hel icase domain in Dicer. The antisense strand of 
the siRNA duplex then binds to the mRNA in a sequence-specific 
manner, Panel B. The binding of the siRNA initiates the RNA­
dependent RNA polymerase (Panel C), which generates double­
stranded RNA to be cleaved by Dicer, Panel D. This process is 
propagated through the generation of more siRNA and continues 
unabated unti l the specific mRNA has been degraded. Adapted from 
Schwarz et al. (92). 
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Figure 5. The "endonucleocytic-cleavage" model. The D. 
melanogaster and mammal ian model for gene s i lencing is 
referred to as the "endonucleocytic-cleavage" model .  The 
"endonucleocytic cleavage" model of gene si lencing involves the 
RISC complex forming with th� siRNA duplex. Double-stranded 
RNA is d igested with Dicer, Panel A. The siRNA duplex is 
unwound by a hel icase in the Dicer enzyme and activates the 
RISC complex, Panel B. The activated RISC binds mRNA in a 
sequence-specific manner (Panel C) and is  cleaved by an 
endonuclease in the activated R ISC complex. Adapted from 
Scwartz et al. (92). 
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cleaved and regenerates the Slicer endonuclease with its siRNA (Figure 5) (92, 
94, 99). This process continues unabated until the mRNA has been degraded 
(92). The protein-endonuclease/siRNA complex co-purifies, indicating the 
stability of the complex (98). 
The length of the dsRNA is integral to the RNAi response initiated by the 
cell (4, 100, 101 ). In an experiment designed to test the relevance of dsRNA 
length, Elbashir et al co-transfected a number of different cell lines with a 
luciferase-reporter plasmid and 0.21 µg of siRNA or a longer dsRNA duplex (4). 
They observed siRNA specifically targeted the luciferase reporter gene, while the 
longer dsRNA duplexes strongly and nonspecifically reduced the reporter gene 
expression (4). The nonspecific reduction of reporter gene expression was 
attributed to an interferon response mounted by the cell against the dsRNA (4, 
100, 101). The length dependence of 21-23 mer formation is thought to be a 
mechanism to prevent the undesired activation of RNAi by intramolecular base 
paired, non-pathogenic RNA structures (5). The location of the siRNA sequence 
homology is imperative for the success of the silencing effect and a single base 
pair mismatch can result in up to a 10% difference in efficacy (29, 102-104). 
The range of RNAi applications for cancer include drug discovery, 
treatment, abolishing drug resistance, and cell cycle regulation (105-110). 
Similarly, RNAi has been explored both in CML and in Ph-positive cell lines in an 
attempt to silence the Ber-Ab/ oncogene (25, 26, 28, 29, 31, 111-113). Since 
normal cells lack the Ber-Ab/ fusion gene, it provides a prime molecular target for 
RNA interference (25, 26, 28, 29, 105, 106, 114, 115). The efficacy of targeting 
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this translocation has proven successful in a number of RNAi studies and this 
treatment has been effectively appl ied in both peripheral blood CML cel ls in vitro 
and a number of Ph-positive cel l  l ines, including the K-562 cel l  l ine (28 ,  29, 1 1 3 ,  
1 1 4). The long half-l ife of the Bcr-Abl protein ,  which is greater than 48 hours,  has 
posed a problem in molecular therapies that target the Bcr-Abl gene (1 5, 1 1 7) .  
This problem has been overcome using various methods designed to sustain the 
antisense or siRNA within the cel l  longer than 48 hours (30, 1 1 8) .  
Apoptosis 
Apoptosis (programmed cel l  death) is the result of a sequence of events 
leading to the suicide of a cel l  (Figure 6) (1 1 9) .  Its function is vital to an organism 
and is essential in  normal cel l  turnover, development of the immune system, 
embryonic development, metamorphosis, and hormone-dependent atrophy 
(1 20) . The apoptotic mechanism of death occurs in two distinct phases: a 
commitment to cel l  death , fol lowed by an execution phase, where standard 
morphological and biochemical changes occur ( 1 20). Some of the standard 
characteristics of apoptotic cell death are condensation and fragmentation of the 
nuclear chromatin, compaction of the cytoplasmic organel les , di lation of the 
endoplasmic reticulum, decreasing cell volume, and alterations to the cel l  
membrane resulting in  the recognition and phagocytosis of apoptotic cel ls, which 
prevents an inflammatory response (1 20). The apoptotic process can be in itiated 
by a variety of cel lular insults including DNA damage, and cytotoxicity ( 1 2 1 ) . It 
can also be induced in the cel l  by intracellular factors such as the up-regulation 
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Figure 6. Apoptotic pathway. Overview of apoptotic pathway 
shows DNA damage and cytotoxic agents leading to activation of 
caspases 8 and 1 0. This triggers the mitochondrial membrane 
potential col lapse to release cytochrome c, which is inhibited by 
Bel-XL. Cytochrome c results in activation of caspases 3 and 7 
and leads to cel l  death. 
of either tumor necrosis factor or p53 (122). The consequence of the apoptosis 
pathway is the death of a cell without an inflammatory· response (119). The 
apoptosis cascade consists of a variety of proteins, such as caspases, and 
members of the Bcl-2 protein family (120, 123). To date, mammalian cells have 
been reported to have 12 caspases present in the zymogen, the inactive form, to 
prevent accidental cell death (124). Caspases are present in three types: the 
initiators, the executioners, and the inflammatory caspases (1 24). The initiators, 
caspases 2, 8, 9 and 10, begin the death cascade, where, through a system of 
biochemical signals originating from either extracellular or intracellular 
environment, the executioner caspases, 3, 6, 7, are activated (124). 
The sequence of events during apoptosis begins with the death signal, 
from either the extracellular environment, or the intracellular matrix (124). The 
membrane proteins TRAIL, TNF-R1, Fas, or Perforin can all receive and transmit 
this death signal (125). Caspases 2, 8, and 10 are then activated and proceed to 
initiate the collapse of the mitochondrial membrane (120). The collapse of the 
mitochondrial membrane leads to the release of cytochrome c into the cytosol 
(126). The activity of caspases 3 and 7 is promoted by the presence of 
cytochrome c in the cytosol (126). Caspase 3 is the primary executioner caspase 
and has been shown to cleave and activate the DNA fragmentation factor (OFF), 
resulting in the DNA fragmentation step in apoptosis (126). Proteins that function 
in promoting apoptosis are Bax, Bak, Bad, and Bcl-xs, among others (127). 
Proteins that serve to inhibit this process include Bcl-2, Bcl-xL, and Akt, among 
others (126, 127). 
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It has been discovered that Bcr-Abl serves as a negative regulator of a 
number of apoptotic pathways (51 ). One pathway for this regulation is through 
the inhibition of the release of mitochondrial cytochrome c and other pre­
apoptotic mitochondrial events (126). This interference results in caspase 3 
remaining inactive and the inhibition of apoptosis (126). Protection from 
apoptosis is achieved through Bcr-Abl initiating two mechanisms: constitutive 
activation of STATS, and suppression of SHIP1 expression, resulting in elevated 
levels of phosphatidylinositol (3,4,5)-triphosphate (24 ). Constitutive activation of 
STATS subsequentially leads to the upregulation of the antiapoptotic protein Bel­
XL (39, 128, 129). Bcl-xL prevents perforation of the mitochondrial membrane, by 
functioning as an antagonist of the Bax-Bak heterodimer (124). This inhibition of 
Bax-Bak prevents the release of cytochrome c and other apoptotic promoters 
(124). The Bcl-xL/Bax-Bak interaction is corroborated by the inhibition of Bcr-Abl 
resulting in the down regulation of Bcl-xL (39, 72). This down-regulation induces 
cell differentiation and leads to apoptosis through a number of death-inducing 
agents ( 1 26, 1 29-1 33) . The proposed interaction of Bcr-Abl with STATS, involves 
the Tyr177 residue of Bcr-Abl, which shares homology with the tyrosine 
phosphorylation site of STATS (128). Down-regulation of STATS abrogates Bcr­
Abl-dependent protection from apoptosis and leukemogenesis (128). 
Based on this review of the literature it was hypothesized that targeting 
both the Bcr-Abl oncogene and protein using RNA interference and Gleevec in 
the K-562 cell line would result in restoration of apoptosis sensitivity. 
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. Chapter 2 
Materials and Methods 
Cel l  Culture 
K-562 cells, subline F 1 ,  were passaged weekly in Eagle's minimal 
essential medium supplemented with 15% fetal bovine serum (FBS) (GIBCO 
BRL, Grand Island, NY), plus nonessential amino acids with an inoculum of 1 .5 x 
104 cells/ml (134). The cultures were incubated at 37°C in 5% CO2. K-562 cells 
from 1 0  ml cultures were pelleted, the supernatants removed, and the pellets 
resuspended in 10 ml RPMI 1640 medium supplemented with L-glutamine, 10% 
FBS, and Gentamicin (800µg/ml) (Sigma, St. Louis, MO) at 37°C in 5% CO2. 
Proliferation 
MTT assay 
Mitochondrial function was assayed colorimetrically through the 
conversion of the substrate, MTT (3-[4,5-Dimethylthiazol-2-yl]-2,5-diphenyl­
tetrazolium bromide) (Sigma, St. Louis, MO). Reactions, 0.5ml, were performed 
in 24-well plate where K-562 cells (subline F1) were incubated with at 37°C with 
5% CO2 for two hours in the presence of 500µg/ml MTT. The cells were 
centrifuged at 1 4,000 x g for 5 minutes and the supernatant removed. The cells 
were lysed by vortexing in 700µ1 2-propanol for 5 minutes. Equal aliquots were 
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assayed in quadruplicate on a 96-well plate with a propanol blank read by an 
EL340 microplate reader (Biotek, Winooski, VT) at a wavelength of 570nm with a 
background subtraction of 630-690nm (135). 
[3H]-thymidine incorporation assay 
Incorporation of tritiated thymidine ([3H]-thymidine) ( ICN, Newport Beach, 
CA) was assayed using 0.25µCi in 50µ1 complete RPMI 1640 media. 100µ1 K-
562 cells (subline F1) suspended in complete RPMI 1640 media were co-cultured 
with 50µ1 tritiated thymidine in quadruplicate for 4 hours at 37°C with 5% CO2. 
The cells were harvested with a cell harvester (Skatron Instruments, Inc. , 
Sterling, VA) and radioactivity was assayed at counts per minute (cpm) in a 
Packard (Downer's Grove, IL) liquid scintillation analyzer (136). 
Apoptosis 
Mitochondrial Membrane Potential Assay 
To measure apoptosis, two different methods were used : 1) measurement 
of loss . of the mitochondrial membrane potential ( 137) 2) measurement of the 
activity of the caspase 3 enzyme (138). The JC-1 bi-fluorescent dye was used to 
measure apoptosis by flow cytometry. The green, monomeric dye is absorbed 
into the mitochondria in healthy cells and reaches a critical concentration where it 
then aggregates and emits red light. The loss of the red signal is the measure of 
apoptosis. K-562 cells were pelleted at 2200 ,, x g for, 10 minutes and the ... '- ;.� C 
supernatant removed. The cells were then resuspended in 1 ml PBS, [137mM 
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NaCl, 2.7mM KCI, 10mM Na-PO4, pH 7.4] (lnnoGenex, San Ramon, CA) in the 
presence of 5µg/ml JC-1 bi-fluorescent dye (Molecular Probes, Eugene, OR) with 
vigorous pipetting and incubated on a rocker at 37°C with 5% CO2 for 20 
minutes. The cells were centrifuged at 2000 x g for 5 minutes and the 
supernatant removed. Cells were washed twice with 1ml of PBS and centrifuged 
at 2000 x g for 5 minutes and the supernatant removed. The cells were 
resuspended in 500µ1 PBS and a total of 10,000 events were assayed using flow 
cytometry. As cells progressed into apoptosis, the early depolarization of the 
mitochondria was a reliable qualitative method for identifying programmed cell 
death (137). 
Caspase 3 Assay 
To measure caspase 3 activity, K-562 cells were pelleted at 2200 x g for 
10 minutes and lysed with 100µ1 lysis buffer (Chemicon, Temecula, CA). 20µ1 
total protein lysate was then incubated with caspase 3 substrate (ac-DEVD-pNA) 
(Oncogene, La Jolla, CA) in quadruplicate on a 96 well plate for 6 hours. The 
caspase 3 activity was measured at a wavelength of 405nm on an EL340 
microplate reader (Biotek). As the cells underwent apoptosis, the caspase 3 
activity increased (138). 
Cloning 
siRNA synthesis for RNAi involves cloning, isolation and amplification of 
the region of interest, and the subsequent processing of this region into siRNA. 
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This site-specific siRNA is then inserted into the cel l through transfection using 
cationic liposomes and the silencing effect is then assayed through various 
methods including protein quantification, and mRNA degradation. To generate 
siRNA, the Ber-Ab/ fragment was first cloned into the Litmus 28 plasmid vector 
(New England Biolabs, Beverly, MA). 
Primer Design 
Primers specific for Bcr-Abl oncogene were designed according to 
sequence data from the NCBI BLAST database. The sequences used in the 
design of Ber-Ab/ specific primers were identified by accession numbers Y00661 
(Human bcr mRNA) and X1 641 6 (Human c-abl mRNA). The Bcr-Abl forward 
(SS) strand primer begins at base 31 66 with the break point located 21 2 bp 
downstream at base 3378.  The Bcr-Abl reverse (AS) strand primer begins at 
base 468 with the breakpoint located 241 bp upstream at base 227.  The resultant 
PCR product is 453 bp long with the fusion site located approximately in the 
center of the strand. PCR primers were also designed to flank the T? /polylinker 
region for verification of positive colonies. Primers were made by Sigma Genosys 
(Midland, TX) . 
Bcr-Abl Primer Sequence 
Forward (SS): 5'-ggagggagaacatccgggagcagc-3' - position (31 66-31 90) 
Reverse (AS):  5' -gccatttttggtttgggcttcacag-;3' � position ( 468-443) 
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RNA isolation 
K-562 cells were centrifuged at 2200 x g for 10 minutes and the media 
was removed. The cel ls were then lysed with 1 ml TRlzol (lnvitrogen, Carlsbad, 
CA) transferred to 1.5ml sterile tubes and 200µ1 chloroform was added (139). 
The Chloroform/TRlzol cell lysate was vortexed and then centrifuged at 12,000 x 
g for 5 minutes. The upper aqueous phase was then removed and transferred to 
a new tube and an equal volume of acidic (pH 4.6) phenol/chloroform (1:1) was 
added. The tubes were shaken and centrifuged at 12,000 x g for 5 minutes and 
the upper layer was transferred to a new tube. The phenol/chloroform extraction 
was repeated two times. Sodium acetate, pH 5.2, (1:10 volume), 100% ethanol 
(two volumes), and 10µ1 (5mg/ml) linear acrylamide carrier (Ambion, Austin, TX) 
was added and incubated at -80°C for 1 hour. RNA was centrifuged at 14,000 x g 
for 10 minutes and the supernatant removed. The pellet was washed with 80% 
ethanol twice, air-dried for 5 minutes, and resuspended in nuclease-free water. 
For storage, 1.5µ1 RNAse antibody (1 :20 volume) was added to prevent 
degradation during storage. RNA was quantified on a UV spectrophotometer at 
260nm and quantified using the Beer-Lambert law, O.D./260 x 40µg/ml x dilution 
factor = RNA concentration in µg/ml. 
Reverse Transcription-Polymerase Chain Reaction (RT-PCR) 
Once the total RNA was purified, the mRNA served as a template in the 
RT-PCR reaction to generate cDNA. 1.5µ1 (2µg/µ I) RNA was added to 2.5ng/µI 
random hexamer, 1 µM Ber-Ab/ reverse antisense primer, 1.5µ1 nuclease-free 
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water to a total volume of 4µ1 .  The reaction mixture was placed on a heating 
block pre-warmed to 65 °C for 2 minutes, then placed on ice. In a separate tube, 
reverse transcriptase, thermoscript (0.75 units/µI), superscript I I  (10 units/µI), and 
superscript Ill (1 0 units/µI) were used, and RNAse- out (2 units/µI) was added to 
5µ1 2X reaction buffer to a total volume of 6µ1 (lnvitrogen, Carlsbad, CA). The 
reaction mix was combined with the RNA/primer mix to create a total reaction 
volume of 1 0µi'. The reaction was incubated at 25°C for ten minutes to allow for 
primer hybridization, and then transferred to a water bath at 56°C for 90 minutes. 
Polymerase Chain Reaction (PCR) 
The cDNA generated from the RT-PCR was subjected to Ber-Ab/ gene­
specific primer amplification through PCR. The initial reactions were done in 16µ1  
total volume and later reactions were scaled up to 50µ1. For the 16µ1  reaction, 8µ1  
2X PCR Buffer with Enhance component (1ml buffer mix = 200µ1 10X PCR 
Buffer, 400µ1 5X Enhance, 40µ1 10mM dNTP mix, 360µ1 nuclease-free water), 
Taq DNA Polymerase (0.02 units/µI) (Eppendorf, Westbury, NY), 4µ1 cDNA 
template, 1.25µM Ber-Ab/ forward (SS) and reverse (AS) primers, 2µ1 nuclease­
free water. The reaction conditions were as follows: 97°C initial denaturation for 2 
minutes followed by 35 cycles at 94 °C for 1 minute, 55°C for 1 minute, 72 °C for 2 
minutes and ended with an extension at 72°C for 7 minutes. The samples were 
then held a� 4 °C, analyzed on an agarose gel and stored at -20°C for later usage. 
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Real Time PCR 
The real time reactions using the QuantiTect gene expression assay 
system (Qiagen, Gaithersburg, MD) were assembled in triplicate as follows: 
master mix [12.5 µI 2X QuantiTect probe RT-PCR master mix, 2.5 µI 10X 
QuantiTect assay mix (probes were specific for Ber-Ab/ and GAPDH) , 0.25 µI 
QuantiTect RT mix, 4.75 µI RNAse free water] and 5 µI template RNA (diluted 
1 :50 and 1: 100) to a total reaction volume of 25 µI. The cycle parameters were: 
reverse transcription for 30 minutes at 50°C; PCR initial activation step of 95°C 
for 15 minutes; 3 step cycling: denaturation 15 s at 94 °C, annealing/detection 30 
s at 56°C, extension 30 s at 76°C; cycles were repeated for 45 cycles. Standards 
were made for both Ber-Ab/ and for GAPDH through a series of dilutions of RNA 
to concentrations of 250ng/5µI , 1 00ng/5µI , 25ng/5µI ,  1 0ng/5µI , 1 ng/5µ1. These 
standards were used to quantify the levels of Ber-Ab/ and GAPDH expression of 
the experimental groups. 
EcoRV Digestion 
To prepare the Litmus 28i vector (New England Biolabs, Beverly, MA) for 
cloning, the vector was digested with EcoRV at a site in the polylinker located 
between two opposing T7 promoters. The digestion protocol was as follows: 
EcoRV (1 units/µI ,  Promega, Madison, WI), BSA (0.001µg/µI , Promega), 4µ1 NEB 
Buffer 3 (New England Biolabs), Litmus 28i plasmid vector (25ng/µI , New 
England Biolabs), 29.6µ1 molecular grade water to a total reaction volume of 
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40µ1. The digestion mixture was incubated at 37°C for 2 hours, followed by 
incubation at 25°C for 2 hours, and a final heat inactivation at 80°C for 20 
minutes. The linearized vector was confirmed on a 1 % agarose gel and then 
stored at -20°C for later usage. This digestion yielded a blunt, linearized vector 
suitable for cloning. 
Kienow Fragment/T 4 Polynucleotide Kinase Reaction 
·To prepare the Bcr-Abl oncogene fragment for cloning into the Litmus 28i 
plasmid vector, the fragment was digested with Kienow fragment for blunt end 
polishing. The digestion protocol was as follows: Bcr-Abl fragment (37.2ng/µI), 
1 0µI 2X Quick Ligation Buffer (New England Biolabs), dNTP (465µM, 
Eppendorf), Kienow fragment (0.0465 units/µI, New England Biolabs) to a total 
reaction volume of 21 .5µ1 . The Kienow reaction was incubated at 25°C for 1 5  
minutes and then heat killed at 75°C for 20 minutes. This reaction was 
supplemented with 850µM ATP and T4 polynucleotide kinase (0.4 units/µI, New 
England Biolabs) and incubated at 37°C for 30 minutes. The T4 polynucleotide 
kinase reaction was then heat inactivated at 65°C for 20 minutes. The final 
concentration of the modified Ber-Ab/ oncogene fragment was determined to be 
40ng/µI on a 2% agarose gel. 
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Ligation of Ber-Ab/ into Litmus 28i Plasmid Vector 
Ligation reactions were assembled in two different reactions of 
vector: insert ratios, 1 :3 and 1 :4. The 1 :3 vector: insert reaction was as follows: 
Litmus 28i plasmid vector (20ng/µI), Ber-Ab/ (10ng/µI) oncogene fragment insert, 
Quick DNA Ligase (0.2 units/µI, New England Biolabs), and 2X Quick Ligation 
Buffer (New England Biolabs) to a total volume of 5.5µ1. The 1 :4 vector: insert 
reaction was as follows: Litmus 28i plasmid vector (18.5ng/µI), Bcr-Abl oncogene 
fragment insert (12.5ng/µI), Quick DNA Ligase (0.15 units/µI, New England 
Biolabs), and 2X Quick Ligation Buffer (New England Biolabs) to a total volume 
of 6.5µ1. To verify the presence of Bcr-Abl insert-positive Litmus 28i plasmids, the 
l igation reaction was digested with EcoRV to eliminate the background and then 
subjected to PCR with the Litmus 28i specific primers flanking the site of insertion 
into the vector. 
Transformation of Ligation into Competent E. coli Cells 
In a sterile 5ml tube, 2.5µ1 of the ligation reaction digested with EcoRV 
was incubated with 25µ1 Nova Blue competent cells (Novagen, Madison, WI) on 
ice for 30 minutes. The cell/ligation mix was then heat shocked at 42°C for 
1 minute and then placed on ice for 2 minutes. 150µ1 of prewarmed SOC media 
was added to the cell/ligation mix and incubated at 37 °C, shaking at 225rpm for 1 
hour. The cells were then plated onto prewarmed LB agar plates with 1 00µg/ml 
Carbenicillin (lnvitrogen), and incubated at 37°C overnight. Five colonies were 
selected and tested through PCR ampl ification with the Litmus primers. Positive 
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colonies were grown overnight, plasmid preps were made for siRNA generation 
and glycerol stocks were prepared and stored at -80°C. These positive clones 
were sequenced to verify accuracy of the sequence as compared to the 
published BLAST data. 
siRNA Generation 
Double-stranded DNA was obtained through the PCR of the Litmus 
28i/Bcr-Abl as well as the Litmus 28i/LitMal insert with T7 primers under these 
conditions: 97°C initial denaturation for 2 minutes followed by 35 cycles at 94 °C 
for -1 minute, 55°C for 1 minute, 72 °C for 2 minutes and ended with an extension 
at 72 °C for 7 minutes, holding at 4°C. DNA was then subjected to T7 RNA 
Polymerase amplification to generate double stranded RNA. The reaction 
protocol was as follows: template DNA (1 OOng/µI), 2µ1  1 OX Reaction Buffer, 8µ1 
NTP mix, 2µ1 T7 RNA ' Polymerase (Ambion), and nuclease-free water to a total 
reaction volume of 20µ1. The reaction was incubated at 37°C for 2 hours followed 
by a digestion with DNAse 1 and RNAse A to eliminate the DNA template and 
single stranded RNA. The digestion protocol is as follows: 20µ1 T7 RNA 
Polymerase reaction, 21 µI nuclease free water, 5µ1 1 OX Digestion Buffer, DNAse 
1 (0.8 units/µI), and RNAse A (40pg/µI) to a total reaction volume of 50µ1, was 
incubated at 37°C for 1 hour. The product was column purified, quantified with 
A2so and analyzed on a 1.5% agarose geL The final step in generating the siRNA 
involved the digestion of the double-stranded RNA with RNAse Ill as follows: 
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dsRNA (300ng/µI), 5µ1 10X RNAse I l l  Buffer, RNAse I ll (0.3 units/µI, Ambion), 
and nuclease-free water to a total reaction volume of 50µ1. The RNAse 1 1 1  
digestion reaction was incubated at 37°C for 1 hour and the siRNA were column 
purified and quantified with A2so and analyzed on a 12% polyacrylamide gel. 
Transfection 
Transfection was carried out with varying molar concentrations of siRNA 
with a set amount of RNAifect (Qiagen). Transfection protocol was as follows: in 
a sterile PCR tube siRNA was diluted in RPMI 1640 media, 10% serum (Atlanta 
Biologicals) with gentamicin to a total volume of 100µ1. RNAifect, 10µg/ml, at a 
ratio of 6µI :1µg siRNA was added to 100µ1 siRNA mix and incubated at room 
temperature for 25 minutes to allow for complex formation. After formation, the 
complex was then added to the K-562 cells suspended in 100µ1 RPMI 1640 
media, 10% FBS, with gentamicin in a 24-well plate in a total transfection volume 
of 200µ1 to transfect for 4 -10 hours at 37°C with 5% CO2. Upon completion of the 
transfection, the cells were then added to 10ml flasks with RPMI 1640 media, 
with 10% FBS and Gentamicin (80µg/ml) and grown for the duration of the 
experiment at 37°C with 5% CO2. 
Western Blot 
K-562 cells were pelleted at 2,200 x g for 5 minutes and the supernatant 
removed. The cells were lysed in Chaps Cell Extract Buffer [50mM Pipes/NaOH 
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(pH 6.5), 2mM EOTA, 0.1% Chaps, 5mM OTT, 20 µg/ml Leupeptin, 10 µg/ml 
pepstatin, 10 µg/ml aprotinin, and 1 mM PMSF] for 30 minutes on ice. The lysate 
was centrifuged at 14,000 rpm for 10 minutes and the supenatant transferred to a 
new tube. Protein concentration was quantified using Bradford analysis on an 
EL340 microplate reader (Biotek) and 65µg total protein used in western blot 
assay. 
The protein was loaded into a 6% SOS denaturing gel and 
electrophoresed at 125V for 1 ½ hours. The protein was transferred onto a 
nitrocellulose membrane at 70V at 4 °C for 1 hour. The nitrocellulose membrane 
was blocked using casein for 1 hour. Primary antibodies: a-rabbit Ber (Santa 
Cruz Biologicals, Santa Cruz, CA), a-rabbit Bcl-xL (Spring Bioscience, Fremont, 
CA) dilutions of 1:1000 in casein, was applied on nitrocellulose membrane at 4°C 
overnight with shaking. The membrane was washed 3 times for 5 minutes in 
TBST and the secondary antibody, a-rabbit lgG conjugated with horseradish 
peroxidase (dilution of 1 :5000 in casein), was applied to the membrane with 
shaking for 1 hour. The membrane was washed 5 times for 5 minutes in TBST 
and the substrate was applied for 5 minutes. The protein was visualized using X­
ray film. 
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Chapter 3 
Results 
Gleevec 
Proliferation was measured using two independent assays, MTT salt 
conversion, which quantified the loss of mitochondrial membrane potential, and 
[
3H]-thymidine uptake, which determined the level of DNA synthesis. Both of 
these proliferation studies were set up to establish the ICso, where 50% viabi l ity 
was present, of Gleevec was establ ished in the F1 subline of K-562 cells. 
Through a series of time-course, dose response experiments performed in 
triplicate over the course of three weeks, the average of all the proliferation data 
was compiled into a dose response curve of Gleevec. From these averages the 
IC50 was determined. Time points were taken at 24, 48, 72, and 96 hours to 
determine the optimal time for assaying the effects of Gleevec; the data from 
times 24 hours and 96 hours was not included. In both the MTT and the [3H]­
thymidine uptake experiments, the ICso of Gleevec was found to be 0.2 µM 
(figures 7 and 8). Both time points 48 and 72 hours were used for later studies. 
The next study measured the level of apoptosis in response to the stress 
of Gleevec through both caspase 3 activity and loss of mitochondrial membrane 
potential. In this study the empirical IC5o found through proliferative measure was 
corroborated by apoptosis experiments to confirm that the decl ine in proliferation 
was, in fact, due to programmed cel l  death. 
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Figure 7. The ICso of Gleevec determined by MTT reduction. 
An average of 3 weeks data (n = 9) of the K-562 sub line F 1 co­
cultured with varying doses of Gleevec assayed at 48 and 72 
hours indicated the ICso of Gleevec to be 0.2µM. 
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Figure 8. The ICso of Gleevec determined by [3H]-thymidine 
uptake. An average of 3 weeks data (n = 9) of the K-562 subline 
F1 co-cultured with varying doses of Gleevec assayed at 48 and 
72 hours indicated the IC50 of Gleevec to be 0.2µM. 
Caspase 3 activity is shown to be elevated as a response to increasing 
doses of Gleevec at 48 and 72 hours (Figures 9 and 1 0) .  There was baseline 
caspase 3 activity up to 0 .2 µM, but doses beyond this resulted in a greater than 
5-fold increase in caspase 3 activity at both 48 and 72 hours. The mitochondrial 
membrane integrity measured by FACS analysis is shown in response to 
Gleevec stress at 48 and 72 hours (Figures 1 1  and 1 2) .  With doses above 0.2 
µM, Gleevec induces a greater than 5-fold increase in apoptotic cells at 48 hours, 
and a greater than 20-fold increase in apoptotic cells at 72 hours. 
Proliferative decline was determined to be a result of apoptosis as [3H]­
thymidine data at 48 and 72 hours was co-plotted with caspase 3 data at 48 
hours and 72 hours (Figures 1 3  and 14) .  This inverse relationship shows 0.2 µM 
Gleevec as the effective dose at both inducing apoptosis and reducing viability by 
50%. These findings corroborate the previously published Gleevec ICso of 
0.25µM (34, 35) . 
The Ber-Ab/ fusion gene was cloned into the Lit 28 RNA transcription 
vector (Figure 1 5) used to in vitro transcribe double-stranded RNA for making 
siRNA to be used later in the study. The blunt, non-directional method of cloning 
was chosen because the orientation was irrelevant. The Ber-Ab/ fusion gene 
product, 450bp, and the Lit28i vector was gel purified and prepared for ligation 
(Figure 1 6) .  To measure the success of the reaction, the ligation product was 
digested with EcoRV and subjected to PCR (Figure 1 7) .  This digestion limited the 
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Figure 9. Apoptosis measured by caspase 3 activity at 48 hours. 
Apoptosis determined by caspase 3 activity in the K-562 subline 
F1 co-cu ltured with varying doses of Gleevec assayed at 48 
hours indicated that doses greater than 0 .2µM induced 
apoptosis. 
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Figure 10. Apoptosis measured by caspase 3 activity at 72 
hours. Apoptosis determined by caspase 3 activity in the K-562 
subline F 1 co-cultured with varying doses of Gleevec assayed 
at 72 -hours indicated that doses greater than 0.2µM induced 
apoptosis. 
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Figure 1 1 .  Mitochondrial membrane potential at 48 hours. The 
K-562 subline F1 co-cultured with varying doses of Gleevec 
indicated that doses greater than 0.2µM induced apoptosis at 
48 hours. 
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Figure 12. Mitochondrial membrane potential at 72 hours. The 
K-562 sub line F 1 co-cultured with varying doses of Gleevec 
indicated that doses greater than 0.2µM induced apoptosis at 
72 hours. 
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Figure 13. Apoptosis and proliferation at 48 hours. 
Apoptosis and proliferation co-plotted against dose of 
Gleevec at 48 hours indicated that the decline in 
proliferation was attributed to apoptotic cel l  death . The 
two lines intersect at 0.3µM Gleevec. 
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Figure 14. Apoptosis and proliferation at 72 hours. 
Apoptosis and proliferation co-plotted against dose of 
Gleevec at 72 hours indicated that the decline in 
proliferation was attributed to apoptotic cel l  death . 
The lines intersect at 0.3µM Gleevec. 
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Figure 15. The Litmus 28i plasmid vector. The Litmus 28i 
plasmid vector used for in vitro production of siRNA 
contains two opposing T7 promoters. The Ber-Ab/ fusion 
gene was cloned into the polylinker region at the blunt 
EcoRV site. 
450b 
Figure 1 6. Purification of the Bcr-Abl PCR product for 
cloning . 1  % agarose gel stained with ethidium bromide. PCR 
product of BCR-ABL fragment, cut from this gel and then purified 
using the Wizard PCR cleanup kit (Promega). Lanes 1 -9 :  BCR­
ABL fragment 1 (450bp), Lane 1 0 : negative control (no 
template), Lane 1 1 :  EcoRV d igested Litmus 28i plasmid. 
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Figure 1 7. Confirmation of Bcr-Abl positive clones through 
PCR. Panel A: Ligation reaction was d igested with EcoRV and 
PCR confirmed the presence of the Ber-Ab/ insert. Panel B :  
Plasmid DNA was isolated , column purified and PCR 
confirmed the Ber-Ab/ positive colonies . 
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background of the re-ligated vector and allowed for confirmation of the ligation for 
procession to the next step of transformation. Following the ligation and the 
transformation into competent Escherichia coli cells, five colonies were present. 
Of these five colonies, three were found to be positive for the Ber-Ab/ insert 
(Figure 17). Through restriction endonuclease digestion, two of the three colonies 
were confirmed to be positive for the Ber-Ab/ insert (Figure 18). This step was 
confirmed through additional PCR (data not included) and through sequencing 
(Figures 19 and 20). 
Fol lowing the confirmation of the Bcr-Abl insert, the Bcr-Abl-specific siRNA 
were made through amplification with T7 RNA polymerase (Figure 21) and 
digested with RNAse Ill (140). This product yielded 15-19 nucleotide duplexes 
homologous to the 450 bp region of the Bcr-Abl insert. The integrity of these 
siRNA is shown in Figure 22. 
Transfection at first proved to be a problem and limiting factor in the 
knockdown of the Bcr-Abl transcript .  Transfection efficiency was measured and 
optimized using a non-silencing, fluorescein-labeled siRNA duplex. 
Oligofectamine yielded 25% transfection efficiency as measured through flow 
cytometry (Figure 23), and was not detectable using fluorescent microscopy. 
Delivery the siRNA into the K-562 cel ls was accomplished using RNAifect, with 
consistent efficiencies of 90% or better as measured through both flow cytometry 
(Figure 23) and fluorescent microscopy (Figure 24). RNAifect transfections were 
performed in complete media, whereas Oligofectamine transfections were 
performed in the absence of serum and were more cytotoxic. 
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422 bp 
Figure 1 8. Restriction enzyme digestion. 1 % Agarose gel stained with Ethidium 
Bromide. Plasmids 1, 2 and 3 were digested with Hind I l l  to confirm orientation, 
and then double digested with Xhol and Xbal to confirm the size of the insert. 
Lane 1 :  plasmid 1 undigested, Lane 2: plasmid 2 undigested, Lane 3 :  plasmid 
3 undigested, Lane 4: plasmid 1 digested with Hind I l l  (422bp), Lane 5: 
plasmid 1 double digested with Xhol and Xbal (511bp), Lane 6: plasmid 2 
digested with Hind I l l, Lane 7:  plasmid 2 double digested with Xhol and Xbal, 
Lane 8:  plasmid 3 digested with Hind I l l  (422bp), Lane 9:  plasmid 3 double 
digested with Xhol and Xbal (511 bp). 
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Figure 1 9. Sequence data of Lit28i/Bcr-Abl . Litmus sequencing 
primers specific for the Litmus 28 plasmid were used to sequence 
DNA spanning the polylinker region including the cloned Ber-Abt 
insert . Panel A: includes the start of the Bcr-Abl oncogene as wel l  as 
the fusion site Panel B: includes the end of the Bcr-Abl oncogene. 
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Cloned T7 Ber-Ahl Template 
T7 promoter Litmus Polyl inker Site 
5'taatacgactcactatagggcagatcttcgaatgccatcgcgcgcaccgtacgtctcgaggaattcctgcag 
gggagggagaacatccgggagcagcagaagaagtgtttcagaagcttctccctgacatccgtggagctgcag 
atgctgaccaactcgtgtgtgaaactccagactgtccacagcattccgctgaccatcaataaggaagatgatga 
gtctccggggctctatgggtttctgaatgtcatcgtccactcagccactggatttaagcagagttcaaaagcccttc 
agcggccagtagcatctgactttgagcctcagggtctgagtgaagccgctcgttggaactccaaggaaaacctt 
ctcgctggacccagtgaaaatgaccccaaccttttcgttgcactgtatgattttgtggccagtggagataacactct 
aagcataactaaaggtgaaaagctccgggtcttaggctataatcacaatggggaatggtgtgaagcccaaacc 
aaaaatggc�ctctggtaccctctagtcaaggccttaagtgagtcgtattf ccctatagtgagtcgtatta 
3' 
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Litmus Polyl inker Site T7 Promoter 
Figure 20. Sequence of Lit28i/Bcr-Abl .  The Ber-Ab/ fragment was cloned into 
the Litmus 28 vector polyl inker site at the EcoRV site. The Ber-Ab/ gene was 
sequenced and the red text represents the Ber fragment, and the b lue text 
represents the Ab/ fragment. 
Figure 21 . Two different preparations of double-stranded 
RNA. 1 % agarose gel stained with eth idium bromide. Double 
stranded DNA and double stranded RNA generated through 
PCR and RT-PCR respectively. Lane 1 :  PCR DNA product 
(5 1 2bp), Lane 2: Negative control (no primers) , Lane 3: 
Negative control (no template) ,  Lane 4: dsRNA (NEB) ,  Lane 
5: dsRNA (Ambion) ,  Lane 6: Negative control (no enzyme), 
Lane 7:  Negative control (no template). 
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Figure 22. Quantification and integrity of siRNA. Serial 
dilution of double stranded DNA oligo, 20µM stock, used to 
quantify and measure the integrity of the siRNA generated 
from the NEB and Ambion RNAse I l l  enzymes. 12% non­
denaturing polyacrylamide gel stained with ethidium bromide. 
Lane 1 :  10µ1, 20µM DNA oligo, Lane 2:  10µ1, 10µM DNA 
oligo, Lane 3:  10µ1, 4µM DNA oligo, Lane 4: 10µ1, 2µM DNA 
oligo, Lane 5: 1 0µI, 1 µM DNA oligo, Lane 6: 1 0µI Bcr-Abl 
NEB RNAse I l l  enzyme product, Lane 7: 1 0µI Bcr-Abl 
Ambion RNAse I l l  enzyme product, Lane 8:  10µ1 Lit28mal 
Ambion RNAse I l l  enzyme product. 
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Figure 23: Transfection efficiency by flow cytometry. Transfection 
efficiency as measured using a non-silencing fluorescein conjugated siRNA 
duplex through flow cytometry. Panel A: Closed region represents the 
untransfected control , open area represents the Oligofectamine transfected 
K-562 cells . Oligofectamine yielded a 25% transfection efficiency. Panel B: 
Open area represents the untransfected control, the closed green area 
represents the K-562 cells transfected using RNAifect. RNAifect yielded a 
transfection efficiency of 90%. Both transfection reagents were repeated 
several times with similar results. 
5 1  
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A. 
B. 
Figure 24. Transfection efficiency by fluorescent microscopy. 
Fluorescent microscopy, 400X total magn ification, of K-562 cel ls 
transfected with a non-si lencing fluorescein-conjugated siRNA 
stained with Hoescht 33324. Panel A: fluorescein-conjugated 
siRNA, Panel B: untransfected control 
The RNAi effect was measured using three approaches, including serial 
dilution of the RNA, real time PCR, and western blotting to measure the 
modulation of the Bcr-Abl protein. The lowest detectable Ber-Ab/ transcript 
concentration of K-562 RNA was determined through a serial dilution of the RNA 
in the RT-PCR reaction. Concentrations of RNA were high enough to show the 
presence of the Bcr-Abl transcript product, and low enough to il lustrate the 
difference between the RNAi treated cel ls and the untreated. The results of this 
dilution show that the lowest concentration to visualize the Ber-Ab/ transcript 
product on an agarose gel is at 3µg/ml RNA in the RT-PCR reaction (Figure 25) . 
This dilution series was then applied to K-562 RNA transfected with both 
synthetic and transcribed Bcr-Abl-specific siRNA at 48 hours (Figure 26). The 
RNAi effect is visible with 5µg/ml RNA in the RT-PCR, where both the 
transcribed and the synthetic Ber-Ab/-specific siRNA treated cel ls have less Ber­
Abl transcript than the untreated control. When compared to the irrelevant and 
the untreated control in Figure 27, both the synthetic and the transcribed Bcr-Abl­
specific siRNA treated cells showed a remarkable drop in the amount of Bcr-Abl 
transcript, and no relative change in the Aldolase transcript. 
The visible reduction in Ber-Ab/ transcript levels was confirmed to be due 
to mRNA degradation using real time PCR to quantify the levels of Ber-Ab/ 
transcript and the housekeeping gene GAPDH as a control . The synthetic Ber­
Abl-siRNA mRNA was silenced 70% and the transcribed-digested Ber-Ab/-siRNA 
resulted in a 50% knockdown of the Ber-Ab/ mRNA (Figure 28). 
53 
54 
Figure 25: Bcr-Abl RNA threshold. Serial 
d i lutions of total RNA in RT-PCR reactions 
establ ished the range of detection of the Ber-Ab/ 
gene down to 60ng (3µg/ml) template RNA. 1.5% 
agarose gel stained with ethid ium bromide Lane 
1:  12.5 µg/ml RNA, Lane 2: 6.25 µg/ml RNA, 
Lane 3: 3 µg/ml RNA, Lane 4: 1.5 ng RNA, Lane 
5: negative reaction control (no template) 
Bcr-Abl 
Titration of RNA (µg/ml)  in  RT-PCR 
to show RNAi Effect at 48 hours 
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C .  
D .  
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Figure 26. RNAi through RT-PCR at 48 hours. 
PCR of titration of RNA in RT-PCR illustrates the 
degradation of the Ber-Ab/ mRNA at the 5µg/ml 
concentration, 1.5% agarose gel stained with 
ethidium bromide. Panel A: untreated, Ber-Ab/ 
fragment, Panel B: synthetic Ber-Ab/-specific 
siRNA (800nM), Ber-Ab/ fragment, Panel C: 
transcribed Ber-Ab/-specific siRNA (800nM), Ber­
Abl fragment, Panel D:  untreated, A/do/ase 
fragment 
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RNAi Effect at 72 hours 
1 2 3 4 
Figure 27. RNAi at 72 hours. PCR of RT-PCR 
using 5µg/ml total RNA harvested from K-562 
cells at 72 hours shows the degradation of Bcr­
Abl mRNA, 1 .5% agarose gel stained with 
ethidium bromide. Panel A: Ber-Ab/ fragment, 
Panel B: Aldolase fragment. Lane 1 :  untreated , 
Lane 2 :  irrelevant siRNA (800nM), Lane 3 :  
synthetic Bcr-Ab/-specific siRNA (800nM), Lane 
4: transcribed Bcr-Ab/-specific s iRNA (800nM) 
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Figure 28. Real time PCR measuring Ber-Ab/. Real time PCR data 
for Ber-Ab/ mRNA of K-562 cells transfected with 4µg siRNA 
illustrates that the synthetic Bcr-Abl-specific siRNA reduced the 
Ber-Ab/ mRNA of K-562 cells 70% and the transcribed Ber-Ab/ 
siRNA reduced the Ber-Ab/ mRNA 50%, while the negative 
controls show no change of Ber-Ab/ mRNA levels in relation to the 
untreated control. 
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Using the GAPDH as the housekeeping gene control ,  there was an 
unremarkable difference in  the Ber-Ab/ siRNA transfected cel ls compared to the 
untreated and the RNAifect negative control (Figure 29) . 
The modulation of the Bcr-Abl protein proved to be d ifficu lt due to the long 
half-l ife and the h igh transcript number found in K-562 cells (1 5, 27-29). To 
down-regu late the protein two transfections were needed , with one fol lowing 24 
hours after the initial transfection (29) . Cells were harvested 24 hours after the 
second transfection and protein was isolated . The synthetic Bcr-Abl siRNA down­
regulated the Bcr-Abl protein 80% compared to the irrelevant siRNA control 
(Figure 30) . The synthetic Bcr-Abl siRNA also down-regu lated the Bcl-xL protein  
greater than 75% compared to the irrelevant siRNA control ,  suggesting an 
induction of apoptosis (Figure 30) . 
Combination Treatment 
Alone, RNAi and Gleevec are effective, respectively, at reducing the 
amount of Bcr-Abl mRNA and protein. When combined they show possible 
synergism . Proliferation and apoptosis measurements were used to show the 
synergistic relationship between RNAi and Gleevec. The in itial findings supported 
Bcr-Abl-specific siRNA and Gleevec interacting, but the effect was min imal at 
800nM siRNA (Figure 3 1 ) .  When the higher concentration of 1 .6 µM siRNA was 
combined with Gleevec, the RNAi specifical ly lowered the IC50 greater than 2-fold 
at both 48 and 72 hours compared to the negative control (Figures 32 and 33). 
Based on the prol iferation dose response curve established for Gleevec 
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Figure 29. Real time PCR measuring GAPDH. Real time PCR 
data for GAPDH mRNA of K-562 cells transfected with 4µg siRNA 
illustrates that there is little effect on transcription of the 
housekeeping gene, GAPDH as a result of transfection with these 
siRNA. 
59 
60 
1 2 3 4 
Figure 30. Western Blot of Bcr-Abl and Bcl-xL, Bcr-Abl and 
Bcl-xL protein was down-regulated greater than 80% after 
two transfections of synthetic Bcr-Ab/-specific siRNA. Ber 
was used as a loading control. Lane 1 :  RNAifect alone, 
Lane 2: Irrelevant siRNA (4µg), Lane 3 :  synthetic Ber-Ab/­
specific siRNA (4µg), Lane 4: transcribed-digested Bcr-Abl­
specific siRNA (4µg) 
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Figure 31 . 800nM siRNA combination treatment at 48 hours. 
[3H]-thymidine uptake data for K-562 cel ls treated with 800nM 
siRNA as normal ized to the negative control (RNAifect alone) at 
72 hours i l lustrates that as the doses of Gleevec increase, the 
synthetic and transcribed-d igested Bcr-Abl siRNA show a decline 
in  proliferation . 
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Figure 32. 1 .6µM siRNA and Gleevec combination treatment at 48 
hours. [3H]-thymidine uptake data for K-562 cells treated with 1 600nM 
siRNA compared to negative control at 48 hours show a greater than 
two-fold decline in proliferation of the cells transfected with Bcr-Abl­
specific siRNA compared to those transfected with irrelevant siRNA. 
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Figure 33. 1 .6µM siRNA and Gleevec combination treatment at 72 
hours.  [3H]-thymid ine uptake data for K-562 cel ls treated with 1 600nM 
siRNA compared to negative control at 72 hours show a greater than 
two-fold decline in proliferation of the cel ls transfected with Bcr-Abl­
specific siRNA compared to those transfected with irrelevant siRNA. 
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(Figures 7 ,  8 ,  9, and 1 0) the IC50 was lowered greater than 3-fold . Experiments 
were repeated th ree times and points were taken in quadrupl icate. 
The apoptosis data supports synergism of RNAi and Gleevec. When 
functional mitochondria were measured , the level of apoptosis was sign ificantly 
greater in K-562 cells transfected with Bcr-Abl specific siRNA and apoptosis was 
observed at lower concentrations of Gleevec (F igure 34) . These find ings suggest 
a correlation with Bcr-Abl siRNA and Gleevec. 
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Combination Treatment Effect 
on Apoptosis at 72 hours 
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Figure 34. 1 .6µM siRNA and Gleevec treatment induces 
apoptosis. Apoptosis was determined by functional 
mitochondria assay of K-562 cel ls co-treated with 
1 600nM siRNA and Gleevec presented as percent of 
the untreated control at 72 hours. 
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Chapter 4 
Discussion 
RNAi has been established as a means to silence the transcription and 
subsequent translation of a gene both in vitro and in vivo (2 , 4, 1 8 , 1 9 , 28, 29) . 
The Ber-Ab/ translocation is a potent transforming agent in leukemogenesis and 
many studies have focused on its down-regulation (34, 40, 57 , 1 44 ). Studies 
involving antisense and RNAi have been effective in down-regulating the Ber-Ab/ 
oncogene in vitro (1 5, 28, 29, 1 1 8) .  The tyrosine kinase inh ibitor, Gleevec, has 
proven to be an effective inhibitor of the Bcr-Abl protein (32). In th is study, both 
Gleevec and RNAi targeted the Bcr-Abl protein and gene, respectively, allowing 
for both upstream and direct modulation of the same molecular target. 
Previous stud ies aimed at Bcr-Abl mRNA knockdown have been effective 
at abrogating the translation of the Bcr-Abl protein (1 4, 1 5 , 1 1 8) . The down­
regu lation of the Bcr-Abl mRNA restored sensitivity to apoptosis (1 1 8 , 1 41 ). 
Antisense approaches have been effective at down-regulating the Ber-Ab/ 
oncogene in CML primary cel ls and K-562 cel ls and have been approved for 
cl inica l tria ls (1 5, 1 1 8, 1 42). Spil ler et al. reported significant mRNA transcript 
reduction using modified antisense ODN specific for the Ber-Ab/ fusion site,  
a lthough no change in Bcr-Abl expression was observed (1 5) . Protein down­
regulation was unchanged , probably due to the transient nature and instabi l ity of 
the ODN as wel l as the long half-l ife of the Bcr-Abl protein, wh ich has been 
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reported at being greater than 48 hours ( 1 5, 1 1 7) .  Martiat et al. demonstrated 
that the stable expression of the antisense ODN specific for the Ber-Ab/ fusion 
site del ivered using a retroviral vector in K-562 cel ls resulted in a decline in 
proliferation coupled with down-regulation of Ber-Ab/ mRNA and protein ( 1 1 8) .  A 
constant antisense presence resu lted in the Bcr-Abl protein down-regu lation. 
RNAi offers an alternative approach to repress the translation of a specific 
gene, which involves the specific degradation of targeted mRNA ( 1 0 , 1 9) .  Whi le 
RNAi approaches differ from antisense in the mechanism of action , both result in 
translational inhibition . RNAi has proven successfu l in knocking down the Ber-Ab/ 
oncogene, abrogating the production of the Bcr-Ab l protein (28 , 29, 1 1 3) .  In  th is 
study, RNAi was selected to inhibit the Bcr-Ab l gene due to the stabi l ity of double 
stranded siRNA in vitro. Two different siRNA preparations were compared to 
measure the Bcr-Abl gene knockdown . 
The efficacy of siRNA del ivery into the targeted cel l  was critica l ,  and there 
have been several developments aimed at increasing the efficiency of delivery 
(1 1 3 , 1 43). In itia l  experiments with Oligofectamine and Lipofectamine 2000 were 
25% and 5% effective, respectively, as measured by the uptake of a non­
silencing fluorescein-conjugated siRNA duplex by flow cytometry (Figure 22). 
These experiments were performed in serum-free media, which could have 
contributed to low transfection efficiency. Transfection with RNAifect yielded over 
90% siRNA ol igonucleotide uptake in the presence of serum and was selected 
because the transfection cond itions were most similar to cu lture cond itions 
(Figure 22) .  
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Two Ber-Ab/-specific siRNA preparations spanning the Bcr-Abl fusion site 
were compared to evaluate the efficacy of both the synthetic (Qiagen) and 
transcribed-digested, which we prepared (28, 29, 140). The transcribed-digested 
siRNA were generated from a 450 bp fragment spanning the Ber-Ab/ fusion site, 
which yielded a heterogeneous mixture of siRNA, 17-19 nucleotides in length. 
The transcribed-digested preparation encompassed more than the homogenous 
Bcr-Abl breakpoint-specific synthetic siRNA with the anticipation that it would 
offer other sites of gene down-regulation with a single transfection. Ber-Ab/ 
mRNA levels were measured both qualitatively through RT-PCR and 
quantitatively through real time PCR. The transcribed-digested Ber-Ab/ siRNA 
resulted in a 50% down-regulation of the Ber-Ab/ mRNA measured by real time 
PCR (Figure 27) and Ber-Ab/ was not detected using RT-PCR. This supported 
Yang et al. , who observed significant luciferase gene knockdown using 
transcribed-digested siRNA (140). The heterogeneity of our transcribed-digested 
Bcr-Abl siRNA proved to be a disadvantage and was not observed to down­
regulate the Bcr-Abl protein. The heterogeneity of the transcribed-digested 
siRNA could have diluted the effective domains for potent silencing and, as a 
result, there were less siRNA specific for regions that would have produced a 
greater effect. 
Synthetic Bcr-Abl siRNA-transfected cells showed a 70% reduction of Bcr­
Abl mRNA, as measured through real time PCR and were undetected using RT­
PCR, suggesting a more potent knockdown of the Bcr-Abl mRNA (Figure 27). 
These results corroborate Wilda et al. and Scherr et al. , who both reported 70% 
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Bcr-Abl mRNA knockdown using synthetic siRNA, and Li et al. , who reported 
greater than 90% Bcr-Abl knockdown with shRNA (28, 29, 1 1 3). The synthetic 
Bcr-Abl siRNA were also capable of down-regulating both the Bcr-Abl and Bcl-xL 
proteins (Figure 29) . Oetzel et al. observed that down-regulation of the Bcr-Abl 
protein by Gleevec led to down-regulation of Bcl-xL protein (34). This suggested 
that sensitivity to apoptosis had been reversed , as well as underscored the well­
defined relationship of Bcr-Abl and Bcl-xL in K-562 cells (34 ,  39, 57, 1 1 4) .  As was 
observed by Scherr et al. , the synthetic Bcr-Abl siRNA required a second 
transfection 24 hours later to down-regulate the Bcr-Abl protein (29) . The dilution 
of the siRNA through cell divisions and the long half-life of the Bcr-Abl protein 
necessitated a second transfection to deliver the siRNA into the newly divided 
cells . 
Initial studies were focused on determining the proliferative and apoptotic 
effects of varying concentrations of Gleevec in K-562 cells. The antiproliferative 
effect of Gleevec was attributed to specific inhibition of the Bcr-Abl tyrosine 
kinase (32-37) . The range where the effect of G leevec would not mask the effect 
of RNAi when combined was determined through a dose-response curve of 
Gleevec daily, over 4 days .  These initial studies, measured by proliferation 
assays in K-562 cells co-cultured with Gleevec, determined the IC50 to be 0.2 µM 
and demonstrated that 48 hours and 72 hours were the optimal times to observe 
the antiproliferative effect (Figures 7 and 8) . This dose corroborated Buchdunger 
et al. who reported 0.25 µM as the IC50 of Gleevec (35) . Time-points were also 
taken at both 24 and 96 hours, where results at 24 hours were unremarkable and 
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96 reflected an increase in apoptosis . Apoptosis was measured daily over 4 days 
in cells co-cultured with Gleevec . Both caspase 3 activity and mitochondrial 
membrane collapse were elevated as the concentration of Gleevec increased . 
The apoptosis data corroborated 48 and 72 hours as the optimal times to 
observe the apoptotic effects of Gleevec in K-562 cells (Figures 9-1 2) .  The 
correlation with decline in proliferation and increase in apoptosis suggested that 
Gleevec induced apoptosis in K-562 cells (Figures 1 3  and 14) .  There was no 
marked effect in either parameter at 24 hours, and at 96 hours even the control 
was showing an increase in apoptosis. 
Studies investigating the combination of Bcr-Abl-specific siRNA with 
Gleevec involved 3 doses that spanned the IC50. Proliferation was used to 
measure the correlation of siRNA-transfected cells treated with Gleevec because 
the initial studies establishing the IC50 measured proliferation. The findings 
suggested a correlation between the combination of both synthetic and 
transcribed-digested Bcr-Abl-specific siRNA and Gleevec in K-562 cells . The 
established Gleevec IC50 was lowered from 0.2µM to 0.06µM when treated with 
4µg (1 .6µM) Ber-Ahl-specific siRNA, and unaffected with 4µg (1 .6µM) irrelevant 
Lit28mal siRNA, suggesting an association between Gleevec and Ber-Ab/ siRNA 
(Figures 32 and 33) . Lower concentrations of siRNA at 2µg {800nM) resulted in a 
lesser effect, which suggests that the siRNA act in a concentration-related 
manner (Figure 3 1  ). The proposed mechanism for this interaction involves the 
degradation of the Ber-Ab/ mRNA, leading to a decrease in the production of the 
Bcr-Abl protein as shown in Figure 35. The amount of Gleevec required to inhibit 
7 1  
the remaining Bcr-Abl protein was reduced because production of the protein had 
been inh ibited . An increase of apoptosis in cel ls transfected with both Ber-Ab/­
specific siRNA and treated with Gleevec was greater than the level of apoptosis 
observed in cel ls treated with Gleevec alone (Figure 34 ). H igher amounts of 
siRNA used in the transfections were determined to be cytotoxic at levels greater 
than 4µg (data not included) ,  probably due to the higher levels of RNAifect 
required for complex formation . These results were similar to those observed by 
Scherr et al. , who found that synthetic Bcr-Abl siRNA del ivered using 
electroporation sensitized Bcr-Ab/-positive BaF3 cells for treatment with Gleevec 
(30). 
In conclusion , this study suggested a correlation with transfection of K-562 
cells with Bcr-Abl-specific siRNA and treatment with Gleevec. The results 
showed that the effective dose of Gleevec was lowered greater than two-fold 
when primed with Bcr-Abl-specific siRNA. While both siRNA preparations exhibit 
this correlation , the synthetic siRNA preparation resulted in a greater reduction of 
the mRNA. The synthetic Bcr-Abl siRNA required two transfections to down­
regulate the Bcr-Abl protein ,  while the transcribed-d igested showed no effect on 
the Bcr-Abl  protein. To corroborate the down-regu lation of Bcr-Abl ,  Bcl-xL protein 
levels were also reduced in K-562 cel ls transfected twice with synthetic Bcr-Abl 
siRNA, suggesting that apoptosis sensitivity was restored . 
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RNAi 
Bcr-Ab'I 
mRNA 
Gleev,ec 
Bcr-Abl 
protei n 
Figure 35. Proposed RNAi/Gleevec mechanism. The 
proposed mechan ism of RNAi lowering the IC50 of 
Gleevec i nvolves the degradation of the Bcr-Abl transcript 
by Bcr-Abl specific siRNA. The reduction of the Bcr-Abl 
transcript leads to a reduction in the Bcr-Abl protein . With 
less of the Bcr-Abl protein  present, a lower dose of 
Gleevec is required to inh ibit prol iferation. 
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Proposed Further Stud ies 
This project could lead to a variety of stud ies i nclud ing analyzing the RNAi 
effect in K-562 sublines with varying copy numbers of Bcr-Abl as wel l  as using 
d ifferent Bcr-Abl-expressing cel l  l ines to get a wider comparison . A study 
applying RNAi in a Gleevec-resistant K-562 cel l  l ine could provide some i nsight 
on the mechanisms of drug resistance in CML. Another application cou ld involve 
using Bcr-Abl mutants and measuring the efficacy of RNAi specific for Bcr-Abl .  
Studies involving a dual RNAi approach using siRNA for both Bcl-xL and for Bcr­
Abl could be analyzed to determine if there is an add itive relationship between 
the two siRNAs . 
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